

L1 dimer binds Ankyrin

Garapati, PV., Maness, PF.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of CC BY 4.0)
<u>License.</u> For more information see our License.

30/04/2024

https://reactome.org

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142.
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467.
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655.
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph data-base: Efficient access to complex pathway data. *PLoS computational biology, 14*, e1005968.

Reactome database release: 88

This document contains 1 reaction (see Table of Contents)


https://reactome.org Page 2

L1 dimer binds Ankyrin 7

Stable identifier: R-NUL-443049

Type: binding

Compartments: cytosol, plasma membrane



L1 recruits membrane skeletal component ankyrin to cell to cell contact sites in response to cis interaction with homophilic axonin 1/TAG 1 or trans L1 L1 homophilic interaction although in mammalian cells trans binding interactions are not required. L1 interacts with ankyrin proteins through two highly conserved amino acid sequence motifs, LADY and FIGQY.

Ankyrin binding immobilizes L1 molecules in the neuronal plasma membrane. This interaction is required for axon maintenance. L1 also elevates cyclic AMP levels in neurons via ankyrin B and mediates Ca+2 dependent attraction. The L1/ankyrin interaction is a vital determinant of synaptic targeting of retinal axons to the superior colliculus and cooperates with EphrinB/EphB signaling to induce axon branch attraction.

Literature references

Ooashi, N., Kamiguchi, H. (2009). The cell adhesion molecule L1 controls growth cone navigation via ankyrin(B)-dependent modulation of cyclic AMP. *Neurosci Res*, 63, 224-6.

Fink, MY., Gil, OD., Bradley, AE., Sakurai, T., Felsenfeld, DP., Cassella, MR. et al. (2003). Ankyrin binding mediates L1CAM interactions with static components of the cytoskeleton and inhibits retrograde movement of L1CAM on the cell surface. *J Cell Biol*, 162, 719-30.

Thelen, K., Needham, LK., Maness, PF. (2001). Cytoplasmic domain mutations of the L1 cell adhesion molecule reduce L1-ankyrin interactions. *J Neurosci*, 21, 1490-500.

Editions

2008-07-30	Authored, Edited	Garapati, P V.
2010-02-16	Reviewed	Maness, PF.